Clinical trial data over two years showed patients receiving Merck and Moderna's experimental melanoma vaccine were 42 percent less likely to experience cancer recurrence compared to patients who did not receive the vaccine

Research

General research and information gathering from multiple sources

1,392 claims

Cancer & Oncology

Cancer treatment, oncology drug access, hematologic malignancies, and cancer drug policy.

225 claims·158 news stories

Opening sign-in…